03rd March 2022 | Pharma Updates

Takeda Pharma appoints Serina Fischer as GM for India

Serina Fischer has more than 17 years of experience in the biopharma industry, with expertise in marketing, strategy, sales and operations.

India Is the Only Country To Okay Corbevax

However, data relating to the vaccine’s efficacy and safety isn’t available in the public domain, and the basis for the Drug Controller General of India’s approval for the vaccine isn’t very clear.

USFDA Clears First Drug-eluting Contact Lens

Johnson & Johnson Vision Care declared that the US’s drug regulator has okayed its Acuvue Theravision with Ketotifen daily disposable contact lenses.

Valencia Technologies Wins Approval for eCoin® Therapy

USFDA has approved eCoin® leadless tibial neurostimulator for the treatment of urinary urge incontinence, which affects more than 60% of patients with Overactive Bladder.

Lupin Gets FDA Clearance for Sevelamer Hydrochloride Tablets

Sevelamer Hydrochloride Tablets, 800 milligrams is a generic version of Renagel Tablets, 800 milligrams of Genzyme Corporation.

Empagliflozin to Treat Wide Range of Heart Failure

The drug was initially approved to treat type II diabetes, has received three more rounds of USFDA approval since all widening the drug’s scope to treat heart disease.

Hawaii-made Rapid Covid-19 Test Gets Emergency Approval from FDA

Oceanit presented its ASSURE-100 rapid antigen test, which uses a shallow nasal swab to collect a sample and can deliver results in 20 minutes.

Harpoon Therapeutics Gets USFDA Fast Track Designation for HPN217

HPN217 has gotten the USFDA Fast Track designation because it addresses the unmet medical need for patients with relapsed, refractory multiple myeloma who received multiple lines of therapy.

Sharon Labs Buys Res Pharma

Sharon Laboratories has inked a definitive agreement to buy speciality ingredients producer Res Pharma Industriale.

Amryt Get CRL from the USFDA for Oleogel-S10 New Drug Application

The biopharma company has gotten a complete response letter from the FDA regarding its New Drug Application (NDA) for Oleogel-S10, for the treatment of the cutaneous manifestations of Dystrophic and Junctional Epidermolysis Bullosa.